advertisement

---

Journal of Ocular Pharmacology and Therapeutics 18

Showing records 1 to 18 | Display all abstracts in Journal of Ocular Pharmacology and Therapeutics

73280 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Lin CW
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 40-51

---

72888 Topical Ganciclovir in Cytomegalovirus Anterior Uveitis
Antoun J
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 313-318

---

72916 Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma
Stahl E
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 361-365

---

72888 Topical Ganciclovir in Cytomegalovirus Anterior Uveitis
Willermain F
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 313-318

---

73280 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Sherman B
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 40-51

---

72916 Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma
Bremond-Gignac D
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 361-365

---

72888 Topical Ganciclovir in Cytomegalovirus Anterior Uveitis
Makhoul D
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 313-318

---

72916 Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma
Landry T
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 361-365

---

73280 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Moore LA
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 40-51

---

72888 Topical Ganciclovir in Cytomegalovirus Anterior Uveitis
Motulsky E
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 313-318

---

73280 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Laethem CL
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 40-51

---

72916 Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma
Curtis M; Gedif K
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 361-365

---

73280 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Lu DW
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 40-51

---

72888 Topical Ganciclovir in Cytomegalovirus Anterior Uveitis
Caspers L; Relvas LJ
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 313-318

---

72916 Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma
Al Shahwan S
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 361-365

---

73280 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Pattabiraman PP
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 40-51

---

72916 Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma
Dixon ER
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 361-365

---

73280 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Rao PV; deLong MA; Kopczynski CC
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 40-51

---